Brind.

The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.

1 report, 1 independent Updated Aug 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Knight Therapeutics Incyte FDA MCC

How it developed

Newest first. Tap a step to see who reported it.

Jun 8Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.Sub-event
Aug 5FDA approved retifanlimab for MCC treatment, with Incyte supplying Knight Therapeutics for use in Latin America.1 source
- GlobeNewswire

Keep exploring

The entities involved

Knight Therapeutics
Canadian pharmaceutical company

Nothing else this week.
Incyte
American pharmaceutical company
- Incyte, a biotech company based in Wilmington, outperformed the biotech ETF.Thu 13:11
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
MCC
camera operator
- MCC addressed grievances regarding city operations in Mangaluru.Sun 17:10
- MCC is holding the stall allotment process at the Jaganmohan Palace, with Wadiyar urging transparency in the process.Thu 17:11

Related events

Coverage

Newest first; wire copies grouped

Aug 5GlobeNewswireKnight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: